Cytocares Inc

This early-stage study tests the safety of a new drug called CC312 in 18 adults with autoimmune diseases like lupus, rheumatoid arthritis, and scleroderma that have not responded to standard treatments. CC312 works by helping the body's immune cells find and attack faulty B cells…

This early-stage study tests a new drug called CC312 in about 44 adults with B-cell blood cancers (like some lymphomas and leukemias) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it …

This early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either CC312 or a placebo, and researchers will monitor side effects and measure d…

This early-stage trial tests the safety of a new drug, CC312, in 6 adults with lupus, inflammatory myopathies, or systemic sclerosis that have not responded to standard treatments. The study will look for side effects and measure how the drug behaves in the body. It is not expect…